Eventide Asset Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Eventide Asset Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-15,000	Closed	-$1.79M	–	152
2018 Q3	$1.79M	Hold	15,000	–	–	0.07%	120
2018 Q2	$1.53M	Hold	15,000	–	–	0.06%	119
2018 Q1	$1.95M	Hold	15,000	–	–	0.09%	113
2017 Q4	$1.46M	Hold	15,000	–	–	0.08%	117
2017 Q3	$2.21M	Hold	15,000	–	–	0.13%	101
2017 Q2	$2.41M	Hold	15,000	–	–	0.15%	92
2017 Q1	$2.39M	Hold	15,000	–	–	0.16%	91
2016 Q4	$1.82M	Hold	15,000	–	–	0.12%	96
2016 Q3	$2.08M	Hold	15,000	–	–	0.13%	98
2016 Q2	$2.72M	Buy	+15,000	New	+$2.72M	0.17%	90

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eventide Asset Management's SYRS Position: Q4 2018 in Review

Eventide Asset Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2018, closing a stake of 15,000 shares — an estimated $1.79M sold.

Eventide Asset Management first reported a position in SYRS in Q2 2016 and held it in 10 quarters. The position peaked at $2.72M in Q2 2016. 68 funds tracked by Wall St. Rank hold SYRS as of Q4 2018.

Eventide Asset Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Eventide Asset Management sold 15,000 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $1.79M.
Eventide Asset Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2016 and held it in 10 quarters.
Eventide Asset Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.72M in Q2 2016.
68 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Eventide Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.